Plain-English translation of NCT06593327 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to prevent heart disease in people with type 2 diabetes. Some primary care doctors will receive alerts when their diabetic patients have signs of high heart failure risk, along with recommendations to start preventive medications or refer them to heart health specialists. The goal is to catch and treat heart disease risk early, before serious problems develop.
People with type 2 diabetes are at much higher risk of developing heart failure, but many cases aren't caught until it's too late. This trial is testing whether early warning systems and preventive treatment recommendations can help doctors identify and treat at-risk patients before heart damage occurs.
You likely qualify if…
You likely don't qualify if…
If you are a primary care provider, you will be randomly assigned to either receive alerts about your diabetic patients' heart failure risk (with treatment recommendations) or continue with usual care. The trial will track how many of your patients develop heart disease and whether the alert system leads to better outcomes. Your actual patients with diabetes may have blood tests done to measure heart failure risk markers.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Roche Diagnostics GmbH
Enrollment target
~300 participants
Started
February 2025
Primary completion
December 2027
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ambarish Pandey, MD
University of Texas Southwestern Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.